Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 4.4.1.5 - lactoylglutathione lyase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenoma
Low red blood cell levels of deglycating enzymes in colorectal cancer patients.
Adrenal Hyperplasia, Congenital
Extended MHC haplotypes in 21-hydroxylase-deficiency congenital adrenal hyperplasia: shared genotypes in unrelated patients.
Heterozygotes and cryptic patients in families of patients with congenital adrenal hyperplasia (21-hydroxylase deficiency). HLA and glyoxalase I typing and hormonal studies.
Sharing of MHC haplotypes among apparently unrelated patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Alzheimer Disease
20S proteasome and glyoxalase 1 activities decrease in erythrocytes derived from Alzheimer's disease patients.
Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains.
HLA-linked complement markers in Alzheimer's and Parkinson's disease: C4 variant (C4B2) a possible marker for senile dementia of the Alzheimer type.
Levels of Receptor for Advanced Glycation End Products and Glyoxalase-1 in the Total Circulating Extracellular Vesicles from Mild Cognitive Impairment and Different Stages of Alzheimer's Disease Patients.
Restoration of glyoxalase enzyme activity precludes cognitive dysfunction in a mouse model of Alzheimer's disease.
Role for glyoxalase I in Alzheimer's disease.
Anemia, Hemolytic
Major histocompatibility complex markers in patients with nomifensine-induced immune hemolytic anemia.
Asthma
Absolute Quantification of Allergen Glb33 in Rice by Liquid Chromatography-Mass Spectrometry using Two Isotope-Labeled Standard Peptides.
Atherosclerosis
A Glyoxalase-1 Knockdown Does Not Have Major Short Term Effects on Energy Expenditure and Atherosclerosis in Mice.
Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes.
Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice.
Gender difference in glyoxalase 1 activity of atherosclerotic carotid artery lesions.
Methylglyoxal and glyoxalase I in atherosclerosis.
Reduced glyoxalase 1 activity in carotid artery plaques of nondiabetic patients with increased hemoglobin A1c level.
Brain Diseases
Enhancement of glyoxalase 1, a polyfunctional defense enzyme, by quercetin in the brain in streptozotocin-induced diabetic rats.
Breast Neoplasms
A possible regulatory role of 17beta-estradiol and tamoxifen on glyoxalase I and glyoxalase II genes expression in MCF7 and BT20 human breast cancer cells.
Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade.
Effects of methylglyoxal and glyoxalase I inhibition on breast cancer cells proliferation, invasion, and apoptosis through modulation of MAPKs, MMP9, and Bcl-2.
Expression of glyoxalase I and II in normal and breast cancer tissues.
Glyoxalase 1 and protein kinase C? as potential therapeutic targets for late-stage breast cancer.
Glyoxalase 1 expression analysis by immunohistochemistry in breast cancer.
Glyoxalase 1 gene is highly expressed in basal-like human breast cancers and contributes to survival of ALDH1-positive breast cancer stem cells.
Glyoxalase I Ala111Glu gene polymorphism: No association with breast cancer risk but correlated with absence of progesterone receptor.
Glyoxalase I Glu111Ala polymorphism in patients with breast cancer.
Oxidative stress and glyoxalase I activity mediate dicarbonyl toxicity in MCF-7 mamma carcinoma cells and a tamoxifen resistant derivative.
Polymorphisms of the receptor for advanced glycation end products and glyoxalase I and long-term outcome in patients with breast cancer.
Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy.
Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer.
Resveratrol, Curcumin and Piperine Alter Human Glyoxalase 1 in MCF-7 Breast Cancer Cells.
The influence of glyoxalase 1 gene polymorphism on its expression at different stages of breast cancer in Egyptian women.
Triple negative tumors accumulate significantly less methylglyoxal specific adducts than other human breast cancer subtypes.
Up-regulation of the tumor promoter Glyoxalase-1 indicates poor prognosis in breast cancer.
Carcinogenesis
Blockage of Glyoxalase I Inhibits Colorectal Tumorigenesis and Tumor Growth via Upregulation of STAT1, p53, and Bax and Downregulation of c-Myc and Bcl-2.
Changes in concentrations of methylglyoxal, D-lactate and glyoxalase activities in liver and plasma of rats fed a 3'-methyl-4-dimethylaminoazobenzene-rich diet.
Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-I, adiponectin receptor expression and prognosis.
Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics.
Glo1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma.
Inhibitory Effect of Isoflavones from Erythrina poeppigiana on the Growth of HL-60 Human Leukemia Cells through Inhibition of Glyoxalase I.
Potential of glycative stress targeting for cancer prevention.
Carcinoma
Analysis of glyoxalase-I from normal and tumor tissue from human colon.
Cloning and characterization of human colon glyoxalase-I.
Discovery of a nanomolar inhibitor of the human glyoxalase-I enzyme using structure-based poly-pharmacophore modelling and molecular docking.
Glyoxalase 1 as a candidate for indicating the metastatic potential of SN12C human renal cell carcinoma cell clones.
Glyoxalase 1 expression is associated with an unfavorable prognosis of oropharyngeal squamous cell carcinoma.
Glyoxalase 1, regulated by LncRNA MALAT1, promotes malignant development of esophageal squamous cell carcinoma.
Glyoxalase I is differentially expressed in cutaneous neoplasms and contributes to the progression of squamous cell carcinoma.
Glyoxalase I phenotype as a potential risk factor for prostate carcinoma.
Interaction of aldehydes with glyoxalase I and the status of several aldehyde metabolizing enzymes of Ehrlich ascites carcinoma cells.
Oxidative stress and glyoxalase I activity mediate dicarbonyl toxicity in MCF-7 mamma carcinoma cells and a tamoxifen resistant derivative.
The Putative Glyoxalase 1 Inhibitor Piceatannol Exhibits Both Anxiolytic-like and Antitumor Effects in Mice.
Carcinoma, Hepatocellular
Glyoxalase 1 is up-regulated in hepatocellular carcinoma and is essential for HCC cell proliferation
Glyoxalase 1 is up-regulated in hepatocellular carcinoma and is essential for HCC cell proliferation.
Inhibition of Glyoxalase-I Leads to Reduced Proliferation, Migration and Colony Formation, and Enhanced Susceptibility to Sorafenib in Hepatocellular Carcinoma.
The Role of Glyoxalase-I (Glo-I), Advanced Glycation Endproducts (AGEs), and Their Receptor (RAGE) in Chronic Liver Disease and Hepatocellular Carcinoma (HCC).
Carcinoma, Lewis Lung
The Putative Glyoxalase 1 Inhibitor Piceatannol Exhibits Both Anxiolytic-like and Antitumor Effects in Mice.
Carcinoma, Renal Cell
Glyoxalase 1 as a candidate for indicating the metastatic potential of SN12C human renal cell carcinoma cell clones.
Overexpression of glyoxalase system enzymes in human kidney tumor.
Carcinoma, Squamous Cell
Glyoxalase 1 expression is associated with an unfavorable prognosis of oropharyngeal squamous cell carcinoma.
Glyoxalase I is differentially expressed in cutaneous neoplasms and contributes to the progression of squamous cell carcinoma.
Cardiovascular Diseases
Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics.
Methylglyoxal-induced dicarbonyl stress in aging and disease: first steps towards glyoxalase 1-based treatments.
Carotid Artery Diseases
Glyoxalase I and aldose reductase gene polymorphisms and susceptibility to carotid atherosclerosis in type 2 diabetes.
Carotid Stenosis
Reduced glyoxalase 1 activity in carotid artery plaques of nondiabetic patients with increased hemoglobin A1c level.
Celiac Disease
Properdin factor B and glyoxalase 1 polymorphism in celiac disease.
Chronic Limb-Threatening Ischemia
Glyoxalase-1 Overexpression Reverses Defective Proangiogenic Function of Diabetic Adipose-Derived Stem Cells in Streptozotocin-Induced Diabetic Mice Model of Critical Limb Ischemia.
Colonic Neoplasms
Synergistic inhibition of colon cancer growth by the combination of methylglyoxal and silencing of glyoxalase I mediated by the STAT1 pathway.
Colorectal Neoplasms
Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-I, adiponectin receptor expression and prognosis.
Corneal Dystrophies, Hereditary
Linkage analysis in granular corneal dystrophy (Groenouw I), Schnyder's crystalline corneal dystrophy, and Reis-Bücklers' corneal dystrophy.
Dermatitis, Atopic
Absolute Quantification of Allergen Glb33 in Rice by Liquid Chromatography-Mass Spectrometry using Two Isotope-Labeled Standard Peptides.
Diabetes Complications
C332C genotype of glyoxalase 1 and its association with late diabetic complications.
Flow cytometric analysis of glyoxalase-1 expression in human leukocytes.
Glyoxalase 1 and glyoxalase 2 activities in blood and neuronal tissue samples from experimental animal models of obesity and type 2 diabetes mellitus.
Hesperetin ameliorates diabetic nephropathy in rats by activating Nrf2/ARE/glyoxalase 1 pathway.
Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II--a clinical research center study.
Metabolism of the 2-oxoaldehyde methylglyoxal by aldose reductase and by glyoxalase-I: roles for glutathione in both enzymes and implications for diabetic complications.
Methylglyoxal metabolism and diabetic complications: roles of aldose reductase, glyoxalase-I, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenase.
Negative association between erythrocyte reduced glutathione concentration and diabetic complications.
The Antidepressant-Like Effects of Hesperidin in Streptozotocin-Induced Diabetic Rats by Activating Nrf2/ARE/Glyoxalase 1 Pathway.
Diabetes Mellitus
Association of glyoxalase I allotypes with Graves' disease and diabetes mellitus.
Association of reduced glyoxalase 1 activity and painful peripheral diabetic neuropathy in type 1 and 2 diabetes mellitus patients.
Flow cytometric analysis of glyoxalase-1 expression in human leukocytes.
Glyoxalase 1 and glyoxalase 2 activities in blood and neuronal tissue samples from experimental animal models of obesity and type 2 diabetes mellitus.
Increased glyoxalase I levels inhibit accumulation of oxidative stress and an advanced glycation end product in mouse mesangial cells cultured in high glucose.
The combination of loss of glyoxalase1 and obesity results in hyperglycemia.
Diabetes Mellitus, Type 1
HLA-A, B, C, DR antigens, Bf, C4 and glyoxalase I (GLO) polymorphisms in French Basques with insulin-dependent diabetes mellitus (IDDM).
Increased levels of methylglyoxal-metabolizing enzymes in mononuclear and polymorphonuclear cells from insulin-dependent diabetic patients with diabetic complications: aldose reductase, glyoxalase I, and glyoxalase II--a clinical research center study.
Diabetes Mellitus, Type 2
Association of Two Glyoxalase 1 Gene Polymorphisms with Nephropathy and Retinopathy in Type 2 Diabetes.
C332C genotype of glyoxalase 1 and its association with late diabetic complications.
Dicarbonyl Stress and Glyoxalase-1 in Skeletal Muscle: Implications for Insulin Resistance and Type 2 Diabetes.
Effect of metformin treatment in patients with type 2 diabetes with respect to glyoxalase 1 activity in atherosclerotic lesions.
Flow cytometric analysis of glyoxalase-1 expression in human leukocytes.
Glyoxalase 1 and glyoxalase 2 activities in blood and neuronal tissue samples from experimental animal models of obesity and type 2 diabetes mellitus.
Glyoxalase I and aldose reductase gene polymorphisms and susceptibility to carotid atherosclerosis in type 2 diabetes.
The combination of loss of glyoxalase1 and obesity results in hyperglycemia.
Diabetic Angiopathies
The characterisation and functional analysis of the human glyoxalase-1 gene using methods of bioinformatics.
Diabetic Cardiomyopathies
Adeno-Associated Viral Transfer of Glyoxalase-1 Blunts Carbonyl and Oxidative Stresses in Hearts of Type 1 Diabetic Rats.
Diabetic Nephropathies
Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality.
Hesperetin ameliorates diabetic nephropathy in rats by activating Nrf2/ARE/glyoxalase 1 pathway.
Knockdown of Glo1 mimics diabetic nephropathy in non-diabetic mice.
The critical role of methylglyoxal and glyoxalase 1 in diabetic nephropathy.
Up-regulation of glyoxalase 1 by mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats.
Diabetic Neuropathies
Association of reduced glyoxalase 1 activity and painful peripheral diabetic neuropathy in type 1 and 2 diabetes mellitus patients.
Expression of macrophage migration inhibitory factor in footpad skin lesions with diabetic neuropathy.
Diabetic Retinopathy
CANDESARTAN ATTENUATES DIABETIC RETINAL VASCULAR PATHOLOGY BY RESTORING GLYOXALASE-I FUNCTION.
Expression analysis of glyoxalase I gene among patients of diabetic retinopathy.
Glyoxalase I is critical for human retinal capillary pericyte survival under hyperglycemic conditions.
TRPC proteins contribute to development of diabetic retinopathy and regulate glyoxalase 1 activity and methylglyoxal accumulation.
Dyslipidemias
Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics.
Endometrial Neoplasms
Comment on 'Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression'
Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression.
Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression.
Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression.
Response to 'Comment on Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression'
[Expression of glyoxalase I and its effect on cell proliferation and apoptosis in endometrial carcinoma].
Epilepsy
LncRNA NEAT1 affects inflammatory response by targeting miR-129-5p and regulating Notch signaling pathway in epilepsy.
Role of glyoxalase I gene polymorphisms in late-onset epilepsy and drug-resistant epilepsy.
Esophageal Squamous Cell Carcinoma
Glyoxalase 1, regulated by LncRNA MALAT1, promotes malignant development of esophageal squamous cell carcinoma.
Fatty Liver
Correction to: Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease.
Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease.
Fibrosarcoma
cDNA cloning and characterization of human glyoxalase I isoforms from HT-1080 cells.
Proteomic analysis indicates that overexpression and nuclear translocation of lactoylglutathione lyase (GLO1) is associated with tumor progression in murine fibrosarcoma.
Glioblastoma
Biomarker discovery: a proteomic approach for brain cancer profiling.
Glioma
Troglitazone reduces glyoxalase I protein expression in glioma and potentiates the effects of chemotherapeutic agents.
Graves Disease
Association of glyoxalase I allotypes with Graves' disease and diabetes mellitus.
Hemangioma, Cavernous, Central Nervous System
GLYOXALASE I A111E, PARAOXONASE 1 Q192R AND L55M POLYMORPHISMS IN ITALIAN PATIENTS WITH SPORADIC CEREBRAL CAVERNOUS MALFORMATIONS: A PILOT STUDY.
Spectrophotometric Method for Determining Glyoxalase 1 Activity in Cerebral Cavernous Malformation (CCM) Disease.
Hyperglycemia
Compensatory mechanisms for methylglyoxal detoxification in experimental & clinical diabetes.
Decreasing Intracellular Superoxide Corrects Defective Ischemia-induced New Vessel Formation in Diabetic Mice.
Effect of antidiabetic compounds on glyoxalase I activity in experimental diabetic rat liver.
Erythrocyte glyoxalase activity in genetically obese (ob/ob) and streptozotocin diabetic mice.
Glycolytic overload-driven dysfunction of periodontal ligament fibroblasts in high glucose concentration, corrected by glyoxalase 1 inducer.
Glyoxalase 1 Modulation in Obesity and Diabetes.
Glyoxalase 1 Prevents Chronic Hyperglycemia Induced Heart-Explant Derived Cell Dysfunction.
Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats.
Reversal of hyperglycemia-induced angiogenesis deficit of human endothelial cells by overexpression of glyoxalase 1 in vitro.
Upregulation of glyoxalase I fails to normalize methylglyoxal levels: a possible mechanism for biochemical changes in diabetic mouse lenses.
Hypersensitivity
Absolute Quantification of Allergen Glb33 in Rice by Liquid Chromatography-Mass Spectrometry using Two Isotope-Labeled Standard Peptides.
Methylglyoxal and a spinal TRPA1-AC1-Epac cascade facilitate pain in the db/db mouse model of type 2 diabetes.
Methylglyoxal evokes pain by stimulating TRPA1.
Oryza sativa drought-, heat-, and salt-induced RING finger protein 1 (OsDHSRP1) negatively regulates abiotic stress-responsive gene expression.
Hypertension
Grape powder supplementation prevents oxidative stress-induced anxiety-like behavior, memory impairment, and high blood pressure in rats.
Reduction of glyoxalase 1 (GLO1) aggravates cerebrovascular remodeling via promoting the proliferation of basilar smooth muscle cells in hypertension.
Infections
Carbonyl stress phenomena during chronic infection with Opisthorchis felineus.
Defence against methylglyoxal in Group A Streptococcus: a role for Glyoxylase I in bacterial virulence and survival in neutrophils?
Glyoxalase in tumourigenesis and multidrug resistance.
Identification of a maize kernel stress-related protein and its effect on aflatoxin accumulation
Identification of a maize kernel stress-related protein and its effect on aflatoxin accumulation.
[The association between glyoxalase I and paracoccidioidomycosis infection]
Insulin Resistance
Dicarbonyl Stress and Glyoxalase-1 in Skeletal Muscle: Implications for Insulin Resistance and Type 2 Diabetes.
GLP-1 improves adipose tissue glyoxalase activity and capillarization improving insulin sensitivity in type 2 diabetes.
Methylglyoxal-induced dicarbonyl stress in aging and disease: first steps towards glyoxalase 1-based treatments.
Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial.
Preventive Effect of Eucalyptol on the Formation of Aorta Lesions in the Diabetic-Atherosclerotic Rat.
Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combination-Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation.
Intestinal Volvulus
A stress-responsive glyoxalase I from the parasitic nematode Onchocerca volvulus.
Kidney Diseases
RAGE and glyoxalase in kidney disease.
Kidney Neoplasms
Polymorphisms of the receptor for advanced glycation end-products and glyoxalase I in patients with renal cancer.
lactoylglutathione lyase deficiency
Dicarbonyl stress in clinical obesity.
Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient.
Leishmaniasis
Crystallization and preliminary X-ray analysis of Leishmania major glyoxalase I.
Leishmaniasis, Visceral
Glyoxalase I from Leishmania donovani: a potential target for anti-parasite drug.
Leukemia
Further studies on liver glyoxalase I and glyoxalase II. Activity in mice bearing sarcoma 180 and L1210 leukemia.
Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis.
Glyoxalase-I is a novel target against Bcr-Abl(+) leukemic cells acquiring stem-like characteristics in a hypoxic environment.
Inhibitory Effect of Isoflavones from Erythrina poeppigiana on the Growth of HL-60 Human Leukemia Cells through Inhibition of Glyoxalase I.
Studies on methylglyoxal. II. Changes of methylglyoxal level accompanying the changes of glyoxalase I and II activities in mice bearing L1210 leukemia and sarcoma 180.
Troglitazone reverses the multiple drug resistance phenotype in cancer cells.
Leukemia, Lymphoid
Synthesis and evaluation of N-alkanoyl-S-benzyl-L-cysteinylglutamic acid esters as glyoxalase I inhibitors and anticancer agents.
Leukemia, Myeloid
Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells.
Liver Cirrhosis
Imbalance in the glutathione system in Opisthorchis felineus infected liver promotes hepatic fibrosis.
Liver Diseases
Correction to: Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease.
Expression of glyoxalase-I is reduced in cirrhotic livers: A possible mechanism in the development of cirrhosis.
Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease.
The Role of Glyoxalase-I (Glo-I), Advanced Glycation Endproducts (AGEs), and Their Receptor (RAGE) in Chronic Liver Disease and Hepatocellular Carcinoma (HCC).
Lung Neoplasms
Inhibitory Effect of Isoflavones from Erythrina poeppigiana on the Growth of HL-60 Human Leukemia Cells through Inhibition of Glyoxalase I.
Piceatannol, a natural trans-stilbene compound, inhibits human glyoxalase I.
TLSC702, a Novel Inhibitor of Human Glyoxalase I, Induces Apoptosis in Tumor Cells.
Lupus Erythematosus, Systemic
HLA-A,B,C, and DR antigens, GLO I and Bf marker profiles in 75 Cape coloured patients with systemic lupus erythematosus (SLE).
Lymphoma, Non-Hodgkin
The purification and characterization of liver glyoxalase I from normal mice and from mice bearing a lymphosarcoma.
Malaria
Glyoxalase-I activity levels in peripheral blood of Ghanaian Africans with or without Plasmodium falciparum.
Mechanism of action of glycyrrhizin against Plasmodium falciparum.
Tight-binding inhibitors efficiently inactivate both reaction centers of monomeric Plasmodium falciparum glyoxalase 1.
Melanoma
Genetic Target Modulation Employing CRISPR/Cas9 Identifies Glyoxalase 1 as a Novel Molecular Determinant of Invasion and Metastasis in A375 Human Malignant Melanoma Cells In Vitro and In Vivo.
GLO1 overexpression in human malignant melanoma.
Metabolic Syndrome
Thiamine reduced metabolic syndrome symptoms in rats via down-regulation of hepatic nuclear factor-k? and induction activity of glyoxalase-I.
Multiple Sclerosis
Advanced Glycation Endproducts Are Increased in the Animal Model of Multiple Sclerosis but Cannot Be Reduced by Pyridoxamine Treatment or Glyoxalase 1 Overexpression.
Muscular Dystrophies
Glyoxalase enzyme system in human muscular dystrophy.
Myeloproliferative Disorders
Platelet glyoxalases in thrombocytosis.
Neoplasm Metastasis
Genetic Target Modulation Employing CRISPR/Cas9 Identifies Glyoxalase 1 as a Novel Molecular Determinant of Invasion and Metastasis in A375 Human Malignant Melanoma Cells In Vitro and In Vivo.
Glyoxalase 1, regulated by LncRNA MALAT1, promotes malignant development of esophageal squamous cell carcinoma.
Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.
[Metformin--new treatment strategies for gynecologic neoplasms].
Neoplasms
2D- and 3D-QSAR modelling, molecular docking and in vitro evaluation studies on 18?-glycyrrhetinic acid derivatives against triple-negative breast cancer cell line.
A new method for rapidly generating inhibitors of glyoxalase I inside tumor cells using S-(N-aryl-N-hydroxycarbamoyl)ethylsulfoxides.
Addition of hydrophobic side chains improve the apoptosis inducibility of the human glyoxalase I inhibitor, TLSC702.
Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-D-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor.
Analysis of glyoxalase-I from normal and tumor tissue from human colon.
Antitumour activity of S-p-bromobenzylglutathione cyclopentyl diester in vitro and in vivo. Inhibition of glyoxalase I and induction of apoptosis.
Blockage of Glyoxalase I Inhibits Colorectal Tumorigenesis and Tumor Growth via Upregulation of STAT1, p53, and Bax and Downregulation of c-Myc and Bcl-2.
Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade.
Carcinostatic activity of methylglyoxal and related substances in tumour-bearing mice.
Changes in protein expression after neoadjuvant use of aromatase inhibitors in primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance.
Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-I, adiponectin receptor expression and prognosis.
Computational and experimental exploration of the structure-activity relationships of flavonoids as potent glyoxalase-I inhibitors.
Copy number variation of glyoxalase I.
Delphinidin, a dietary anthocyanidin in berry fruits, inhibits human glyoxalase I.
Design, synthesis and biological evaluation of novel glyoxalase I inhibitors possessing diazenylbenzenesulfonamide moiety as potential anticancer agents.
Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics.
Differences among human tumor cell lines in the expression of glutathione transferases and other glutathione-linked enzymes.
Differentiation and apoptosis induction by lovastatin and ?-tocotrienol in HL-60 cells via Ras/ERK/NF-?B and Ras/Akt/NF-?B signaling dependent down-regulation of glyoxalase 1 and HMG-CoA reductase.
Discovery of a nanomolar inhibitor of the human glyoxalase-I enzyme using structure-based poly-pharmacophore modelling and molecular docking.
Effect of piceatannol-rich passion fruit seed extract on human glyoxalase I-mediated cancer cell growth.
Effects of methylglyoxal and glyoxalase I inhibition on breast cancer cells proliferation, invasion, and apoptosis through modulation of MAPKs, MMP9, and Bcl-2.
Effects of vitamin D supplementation on advanced glycation end products signaling pathway in T2DM patients: a randomized, placebo-controlled, double blind clinical trial.
Ellagic acid: A potent glyoxalase-I inhibitor with a unique scaffold.
Embryonic atrazine exposure elicits proteomic, behavioral, and brain abnormalities with developmental time specific gene expression signatures.
Evaluation of potential flavonoid inhibitors of glyoxalase-I based on virtual screening and in vitro studies.
Flow cytometric analysis of glyoxalase-1 expression in human leukocytes.
Glo1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma.
GLO1-A novel amplified gene in human cancer.
Glutathione S-transferases in normal and malignant human colon tissue.
Glycerophosphoglycerol, Beta-alanine, and pantothenic Acid as metabolic companions of glycolytic activity and cell migration in breast cancer cell lines.
Glyoxalase 1 expression analysis by immunohistochemistry in breast cancer.
Glyoxalase 1 Expression as a Novel Diagnostic Marker of High-Grade Prostatic Intraepithelial Neoplasia in Prostate Cancer.
Glyoxalase 1 expression is associated with an unfavorable prognosis of oropharyngeal squamous cell carcinoma.
Glyoxalase 1 gene is highly expressed in basal-like human breast cancers and contributes to survival of ALDH1-positive breast cancer stem cells.
Glyoxalase 1-419C>A Variant Is Associated with Oxidative Stress: Implications in Prostate Cancer Progression.
Glyoxalase activities in human tumour cell lines in vitro.
Glyoxalase activities in tumor and non-tumor human urogenital tissues.
Glyoxalase I (GLO1) is Up-regulated in Pancreatic Cancerous Tissues Compared with Related Non-cancerous Tissues.
Glyoxalase I activity in human prostate cancer: a potential marker and importance in chemotherapy.
Glyoxalase I Glu111Ala polymorphism in patients with breast cancer.
Glyoxalase I in detoxification: studies using a glyoxalase I transfectant cell line.
Glyoxalase I in tumor cell proliferation and survival and as a potential target for anticancer therapy.
Glyoxalase I inhibitors in cancer chemotherapy.
Glyoxalase I is differentially expressed in cutaneous neoplasms and contributes to the progression of squamous cell carcinoma.
Glyoxalase in tumourigenesis and multidrug resistance.
Glyoxalase-1-Dependent Methylglyoxal Depletion Sustains PD-L1 Expression in Metastatic Prostate Cancer Cells: A Novel Mechanism in Cancer Immunosurveillance Escape and a Potential Novel Target to Overcome PD-L1 Blockade Resistance.
Glyoxalase-I is a novel prognosis factor associated with gastric cancer progression.
High expression of GLO1 indicates unfavorable clinical outcomes in glioma patients.
Identification of immunodominant regions of Brassica juncea glyoxalase I as potential antitumor immunomodulation targets.
Identification of the first "two digit nano-molar" inhibitors of the human glyoxalase-I enzyme as potential anticancer agents.
Imaging Tumorous Methylglyoxal by an Activatable Near-Infrared Fluorescent Probe for Monitoring Glyoxalase 1 Activity.
Imidazopurinones are markers of physiological genomic damage linked to DNA instability and glyoxalase 1-associated tumour multidrug resistance.
Inhibition of glyoxalase I by the enediol mimic S-(N-hydroxy-N-methylcarbamoyl)glutathione. The possible basis of a tumor-selective anticancer strategy.
Inhibition of Glyoxalase-I Leads to Reduced Proliferation, Migration and Colony Formation, and Enhanced Susceptibility to Sorafenib in Hepatocellular Carcinoma.
Inhibitory Effect of Isoflavones from Erythrina poeppigiana on the Growth of HL-60 Human Leukemia Cells through Inhibition of Glyoxalase I.
Interdependence of GLO I and PKM2 in the Metabolic shift to escape apoptosis in GLO I-dependent cancer cells.
Long-term intake of the reactive metabolite methylglyoxal is not toxic in mice.
Low red blood cell levels of deglycating enzymes in colorectal cancer patients.
Methylglyoxal-induced dicarbonyl stress in aging and disease: first steps towards glyoxalase 1-based treatments.
Molecular cancer therapeutics: recent progress and targets in drug resistance.
Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal.
Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I.
Phytochemicals against anti-diabetic complications: targeting the advanced glycation end product signaling pathway.
Piceatannol, a natural trans-stilbene compound, inhibits human glyoxalase I.
Polymorphisms of the receptor for advanced glycation end products and glyoxalase I and long-term outcome in patients with breast cancer.
Potential of glycative stress targeting for cancer prevention.
Preventive Effect of Eucalyptol on the Formation of Aorta Lesions in the Diabetic-Atherosclerotic Rat.
Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy.
Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
Proteomic analysis indicates that overexpression and nuclear translocation of lactoylglutathione lyase (GLO1) is associated with tumor progression in murine fibrosarcoma.
Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer.
Recent Advances in Glyoxalase-I Inhibition.
Selenium level and glutathione-dependent enzyme activities in normal and neoplastic human lung tissues.
Structural basis for 18-?-glycyrrhetinic acid as a novel non-GSH analog glyoxalase I inhibitor.
Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects.
Synergistic inhibition of colon cancer growth by the combination of methylglyoxal and silencing of glyoxalase I mediated by the STAT1 pathway.
The Putative Glyoxalase 1 Inhibitor Piceatannol Exhibits Both Anxiolytic-like and Antitumor Effects in Mice.
The tumor promoting phorbol diester, 12-O-tetradecanoylphorbol-13-acetate (TPA) increases glyoxalase I and decreases glyoxalase II activity in human polymorphonuclear leukocytes.
Thermal copoly(amino acids) as inhibitors of glyoxalase I.
TLSC702, a Novel Inhibitor of Human Glyoxalase I, Induces Apoptosis in Tumor Cells.
Triple negative tumors accumulate significantly less methylglyoxal specific adducts than other human breast cancer subtypes.
Tumor necrosis factor-induced modulation of glyoxalase I activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxal-derived AGE.
Tumour necrosis factor induces phosphorylation primarily of the nitric-oxide-responsive form of glyoxalase I.
Up-regulation of the tumor promoter Glyoxalase-1 indicates poor prognosis in breast cancer.
[Metformin--new treatment strategies for gynecologic neoplasms].
Neuritis
HLA antigens in the Landry-Guillain-Barré syndrome and chronic relapsing polyneuritis.
Pathological effects of glyoxalase I inhibition in SH-SY5Y neuroblastoma cells.
Neuroblastoma
Pathological effects of glyoxalase I inhibition in SH-SY5Y neuroblastoma cells.
Neurodegenerative Diseases
C332C genotype of glyoxalase 1 and its association with late diabetic complications.
High-fructose intake as risk factor for neurodegeneration: Key role for carboxy methyllysine accumulation in mice hippocampal neurons.
Role for glyoxalase I in Alzheimer's disease.
Neuroendocrine Tumors
Glyoxalase 1 copy number variation in patients with well differentiated gastro-entero-pancreatic neuroendocrine tumours (GEP-NET).
Non-alcoholic Fatty Liver Disease
Correction to: Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease.
Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease.
Obesity
Dicarbonyl stress in clinical obesity.
Glyoxalase 1 and glyoxalase 2 activities in blood and neuronal tissue samples from experimental animal models of obesity and type 2 diabetes mellitus.
Glyoxalase 1 Modulation in Obesity and Diabetes.
Methylglyoxal-induced dicarbonyl stress in aging and disease: first steps towards glyoxalase 1-based treatments.
Pharmacological Blockade of Cannabinoid CB1 Receptors in Diet-Induced Obesity Regulates Mitochondrial Dihydrolipoamide Dehydrogenase in Muscle.
Oligodendroglioma
Troglitazone reduces glyoxalase I protein expression in glioma and potentiates the effects of chemotherapeutic agents.
Osteoarthritis
Impairment of glyoxalase-1, an advanced glycation end-product detoxifying enzyme, induced by inflammation in age-related osteoarthritis.
Ovarian Neoplasms
Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy.
Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
Overweight
Dicarbonyl stress in clinical obesity.
Improved Glycemic Control and Vascular Function in Overweight and Obese Subjects by Glyoxalase 1 Inducer Formulation.
Methylglyoxal-induced dicarbonyl stress in aging and disease: first steps towards glyoxalase 1-based treatments.
Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combination-Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation.
Pancreatic Neoplasms
Soluble receptor for advanced glycation end-products (RAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer.
Pancreatitis, Chronic
Common variants in glyoxalase I do not increase chronic pancreatitis risk.
Paracoccidioidomycosis
[The association between glyoxalase I and paracoccidioidomycosis infection]
Parasitemia
Glyoxalase-I activity levels in peripheral blood of Ghanaian Africans with or without Plasmodium falciparum.
Parkinson Disease
HLA-linked complement markers in Alzheimer's and Parkinson's disease: C4 variant (C4B2) a possible marker for senile dementia of the Alzheimer type.
Polycystic Ovary Syndrome
Reduced Ovarian Glyoxalase-I Activity by Dietary Glycotoxins and Androgen Excess: A Causative Link to Polycystic Ovarian Syndrome.
Pre-Eclampsia
Evidence for increased methylglyoxal in the vasculature of women with preeclampsia: role in upregulation of LOX-1 and arginase.
Prostatic Hyperplasia
Glyoxalase activities in tumor and non-tumor human urogenital tissues.
Prostatic Intraepithelial Neoplasia
Glyoxalase 1 Expression as a Novel Diagnostic Marker of High-Grade Prostatic Intraepithelial Neoplasia in Prostate Cancer.
Prostatic Neoplasms
A possible regulatory role of glyoxalase I in cell viability of human prostate cancer.
Chemosensitization of carmustine with maitake beta-glucan on androgen-independent prostatic cancer cells: involvement of glyoxalase I.
Exploring glyoxalase 1 expression in prostate cancer tissues: Targeting the enzyme by ethyl pyruvate defangs some malignancy-associated properties.
Glyoxalase 1 Expression as a Novel Diagnostic Marker of High-Grade Prostatic Intraepithelial Neoplasia in Prostate Cancer.
Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control.
Glyoxalase 1-419C>A Variant Is Associated with Oxidative Stress: Implications in Prostate Cancer Progression.
Glyoxalase I activity in human prostate cancer: a potential marker and importance in chemotherapy.
Glyoxalase I phenotype as a potential risk factor for prostate carcinoma.
High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer.
Role of glyoxalase I in the proliferation and apoptosis control of human LNCaP and PC3 prostate cancer cells.
Prostatic Neoplasms, Castration-Resistant
Chemosensitization of carmustine with maitake beta-glucan on androgen-independent prostatic cancer cells: involvement of glyoxalase I.
Proteinuria
Preventive Effect of Eucalyptol on the Formation of Aorta Lesions in the Diabetic-Atherosclerotic Rat.
Renal Insufficiency
Long-term intake of the reactive metabolite methylglyoxal is not toxic in mice.
Renal Insufficiency, Chronic
Glycative Stress and Its Defense Machinery Glyoxalase 1 in Renal Pathogenesis.
Reperfusion Injury
Glyoxalase I overexpression ameliorates renal ischemia-reperfusion injury in rats.
Sarcoma
Further studies on liver glyoxalase I and glyoxalase II. Activity in mice bearing sarcoma 180 and L1210 leukemia.
Studies on methylglyoxal. II. Changes of methylglyoxal level accompanying the changes of glyoxalase I and II activities in mice bearing L1210 leukemia and sarcoma 180.
Synthesis and cytotoxicity of shikimate analogues. Structure:activity studies based on 1-crotonyloxymethyl-3R,4R,5R-trihydroxycyclohex-2-enone.
Sarcoma 180
Further studies on liver glyoxalase I and glyoxalase II. Activity in mice bearing sarcoma 180 and L1210 leukemia.
Studies on methylglyoxal. II. Changes of methylglyoxal level accompanying the changes of glyoxalase I and II activities in mice bearing L1210 leukemia and sarcoma 180.
Seizures
Genetic and Pharmacological Manipulations of Glyoxalase 1 Mediate Ethanol Withdrawal Seizure Susceptibility in Mice.
Glyoxalase 1 and its substrate methylglyoxal are novel regulators of seizure susceptibility.
Inhibition of Glyoxalase 1 reduces alcohol self-administration in dependent and nondependent rats.
Role of glyoxalase I gene polymorphisms in late-onset epilepsy and drug-resistant epilepsy.
Sleep Initiation and Maintenance Disorders
Liquid chromatography-mass spectrometry in-depth analysis and in silico verification of the potential active ingredients of Baihe Dihuang decoction in vivo and in vitro.
Spinocerebellar Ataxias
Linkage studies on glyoxalase I (GLO), pepsinogen (PG), spinocerebellar ataxia (SCA1), and HLA.
Squamous Cell Carcinoma of Head and Neck
Glyoxalase 1 expression is associated with an unfavorable prognosis of oropharyngeal squamous cell carcinoma.
steroid 21-monooxygenase deficiency
Gene frequencies and genetic linkage disequilibrium for the HLA-linked genes Bf, C2, C4S, C4F, 21-hydroxylase deficiency, and glyoxalase I.
Stomach Neoplasms
Glyoxalase-I is a novel prognosis factor associated with gastric cancer progression.
Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer.
Subacute Sclerosing Panencephalitis
Partial C4 deficiency in subacute sclerosing panencephalitis.
Thrombocytosis
Platelet glyoxalases in thrombocytosis.
Tyrosinemias
Representing and reasoning about protein families using generative and discriminative methods.
Urinary Bladder Neoplasms
Discovery of a nanomolar inhibitor of the human glyoxalase-I enzyme using structure-based poly-pharmacophore modelling and molecular docking.
Urolithiasis
Experimental urolithiasis : Part II--a comparative kinetic study of glyoxalase I, glycolate oxidase, alkaline phosphatase & lactate dehydrogenase in the normal rat kidney & bladder & its alterations in urolithiasis.
Vascular Diseases
Genetic predisposition to advanced glycation end products toxicity is related to prognosis of chronic hemodialysis patients.
Glyoxalase I (Glo1) and its metabolites in vascular disease.
Vascular Malformations
GLYOXALASE I A111E, PARAOXONASE 1 Q192R AND L55M POLYMORPHISMS IN ITALIAN PATIENTS WITH SPORADIC CEREBRAL CAVERNOUS MALFORMATIONS: A PILOT STUDY.
Ventricular Dysfunction
Methylglyoxal-Induced Endothelial Cell Loss and Inflammation Contribute to the Development of Diabetic Cardiomyopathy.
Vitamin B 6 Deficiency
Combined glyoxalase 1 dysfunction and vitamin B6 deficiency in a schizophrenia model system causes mitochondrial dysfunction in the prefrontal cortex.